普莱柯股价上涨0.99%至14.24元，主力资金净流入308万元

Core Viewpoint - The company, Pulaike, has disclosed significant progress in product development and will hold an extraordinary shareholders' meeting to review the election of the board of directors [1] Group 1: Product Development - Multiple avian adenovirus series vaccines have received new veterinary drug registration certificates and are being launched in the market [1] - Nearly 10 products, including a recombinant virus vector trivalent inactivated vaccine for avian influenza and a live vaccine for pseudorabies in pigs, have passed initial review or are in the re-examination stage [1] - Several products are currently in clinical trials or laboratory research stages [1] Group 2: Shareholder Meeting - The company will convene an extraordinary shareholders' meeting on March 6, 2026, to review the election of the sixth board of directors and independent directors [1] Group 3: Stock Performance - As of February 27, 2026, Pulaike's stock price closed at 14.24 yuan, with a daily increase of 0.99% and a cumulative increase of 2.45% over the past five days [1] - The trading volume on February 27 was 84.44 million yuan, with a turnover rate of 1.71% [1] - On February 27, there was a net inflow of approximately 3.08 million yuan in main funds, while on February 26, there was a net outflow of 3.09 million yuan, accounting for 6.98% of the daily trading volume [1] - The stock price fluctuated between a high of 14.37 yuan and a low of 13.79 yuan during this period [1] Group 4: Institutional Insights - The average target price set by institutions is 17.00 yuan, indicating approximately 20% upside potential from the current price [1] - Profit forecasts suggest that the company's net profit is expected to grow by 101.14% year-on-year in 2025, with revenue growth projected at 14.65% year-on-year [1] - Recent institutional ratings have been predominantly neutral, with low frequency of research coverage [1]